Azitra Inc (AZTR)

개요 뉴스 가격 이력 토론 예측

Azitra Inc 주식(AZTR)의 최신 뉴스

Azitra Inc (AZTR)

Azitra Inc 주식(AZTR)의 최신 뉴스

AZTR: Planning 2nd Site for ATR-12 Trial - MSN

Azitra stock plunges to 52-week low at $0.46 amid steep decline - Investing.com Australia

500: Something went wrong - Investing.com Canada

Azitra (NYSEAMERICAN:AZTR) Shares Down 3.9% – Here’s Why - Defense World

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PR Newswire

Azitra to Present at BIO-Europe 2024 - BioSpace

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com

Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk

Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com

Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa

Azitra stock plunges to 52-week low, hits $0.49 - Investing.com

Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga

Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia

Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India

AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan

Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire

AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle

FDA fast tracks Azitra's new dermatology treatment - Investing.com

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan

Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com

Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World

Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World

Azitra Inc’s latest rating changes from various analysts - Knox Daily

A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News

Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex

Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News

Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance

Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com

Views of Wall Street’s Leading Experts on Azitra Inc - SETE News

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com

Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex

Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily

FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com

A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News

Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily

Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Understanding AZTR stock ratios for better investment decisions - US Post News

Ratio Revelations: Azitra Inc (AZTR)’s Financial Metrics in the Spotlight - The Dwinnex

Azitra screens first subject in Phase Ib trial of ATR-12 for Netherton syndrome - Clinical Trials Arena

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com

Azitra, Inc. Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of ATR-12 for Netherton Syndrome - Marketscreener.com

AZTR과 유사한 종목